ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

Interactive RPGs Deadline Is Feb. 20

December 13, 1991

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

February 7, 1997

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002

DCBD Board Okays Recombinant DNA Diagnosis Concept, Two Others, But Rejects Three

June 3, 1983

Top 42 CCOPs (According To Priority Scores) Identified; Present Budget Would Draw Payline At 230

April 3, 1987

NCI Preparing RFA for Genetics Network; Patients Want Gene-Environment Studies

August 9, 1996